1.

患者临床特征与疗效

Patient characteristics and tumor responses

Characteristics	n	ORR%	χ2	P	RR	95%CI	P
ORR: objective response rate; RR: relative risk; EGFR-TKIs: epidermal growth factor receptor tyrosine kinase inhibitors.
Male/Femal	75/116	1.3/7.8	3.790	0.052	2.114	0.009-2.010	0.146
No smoker/smoker	145/46	6.2/2.2	1.145	0.285	0.046	0.047-11.741	0.740
≥60/< 60 (yr)	55/136	6.0/5.0	0.080	0.778
2nd line/3nd line above	55/136	7.3/4.4	0.646	0.422	0.015	0.262-4.544	0.904
Non-platinum/Platinum	80/111	2.5/7.3	2.076	0.150	1.498	0.068-1.859	0.221
Non-pemetrexed/Pemetrexed	94/97	1.1/9.3	6.493	0.011	3.869	0.015-0.993	0.049
Pemetrexed and platinum/Pemetrexed	48/27	14.6/3.7	2.146	0.143
Non-pemetrexed/Pemetrexed in 2nd line	27/28	3.7/14.3	4.160	0.041
Non-pemetrexed/Pemetrexed in 3nd line	67/69	1.5/7.2	2.669	0.102
Non-taxanes/Taxanes	121/70	7.4/1.4	3.228	0.072
EGFR-TKIs primary resistance/acquired resistance	51/140	2.0/6.4	1.504	0.220
EGFR-TKIs dramtic progression/gradual and local progession	52/88	7.7/6.1	0.766	0.282